Skip to main content
. Author manuscript; available in PMC: 2009 Apr 1.
Published in final edited form as: Semin Hematol. 2008 Apr;45(2):95–103. doi: 10.1053/j.seminhematol.2008.02.001

Table 4.

Summary of monoclonal antibodies available in CLL/SLL

Antibody Antigen Description Clinical status
IDEC-C2B8 (Rituximab) CD20 Chimaeric FDA approved
Campath-1H (Alemtuzumab) CD52 Chimaeric FDA approved
Ofatumumab (HuMax CD20) CD20 Humanized Clinical trials
Lumiliximab (IDEC-152) CD23 Chimaeric Clinical trials
Epratuzumab (hLL2) CD22 Humanized Clinical trials
Hu1D10 (Apolizumab, Remitogen) 1D10 (HLA-DR β) Chimaeric Clinical trials
CHIR-12.12 CD40 Humanized Clinical trials